Ciphergen Teams With OSU to Develop SELDI-Based Dx for Rare Blood Disorder | GenomeWeb
NEW YORK (GenomeWeb News) — Ciphergen Biosystems today said it has struck an agreement with the Ohio State University Research Foundation to develop and validate a test to help detect the blood disease thrombotic thrombocytopenic purpura.
 
The partnership aims to discover a clinical diagnostic test that can “rapidly detect” deficiencies in the enzyme activity associated with the disorder, commonly called TTP, which affects blood coagulation.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.